Table 4. Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
| Treatment, participant number | Pre- treatment LLM (sex) | Start to end1 of sustained reduction by ≥ 50% (doses2) | Start to end1 of sustained reduction to ≤ 8100 mf/ml (doses2) | Start to end1 of sustained reduction to <30000 mf/ml (doses2) |
|---|---|---|---|---|
| Plac—15 | 46420 (F) | M18-M24 | NA | M18-M24 |
| Plac—17 | 90940 (M) | M14-M24 | NA | NA |
| 2x Alb—2 | 16600 (M) | M14-M24 (2) | M18-M24 (2) | NA |
| 2x Alb—10 | 28120 (F) | M14-M24 (2) | NA | NA |
| 2x Alb—13 | 34120 (M) | M4-M24 (2) | M14-M18 (2) | M4-M24 (2) |
| 6x Alb—1 | 11040 (F) | M14-M24 (2) | M10-M24 (5) | NA |
| 6x Alb—3 | 15500 (M) | M6-M24 (3) | M6-M24 (3) | NA |
| 6x Alb—5 | 22460 (F) | M6-M24 (3) | M10-M21 (4) | NA |
| 6x Alb—6 | 24520 (M) | M14-M21 (6) | M6-M18 (3) | NA |
| 6x Alb—7 | 25520 (M) | M6-M21 (3) | NA | NA |
| 6x Alb—8 | 27240 (M) | M18-M24 (6) | NA | NA |
| 6x Alb—12 | 32040 (M) | M14-M24 (6) | NA | M2-M24 (1) |
| 6x Alb -14 | 41180 (M) | M18-M24 (6) | NA | M10-M24 (5) |
| 6x Alb—15 | 42980 (M) | M14-M24 (6) | NA | M10-M24 (5) |
| 6x Alb—19 | 158400 (M) | M10-M24 (5) | NA | NA |
1 Start and end are provided as the month M of the first and last measurement of the sustained LLM reduction.
2 Doses: number of albendazole doses received before the start of the sustained reduction. The first dose was given at M0
NA: not achieved or not applicable (for reduction to <30000 mf/ml for participants with < 30000mf/ml pre-treatment LLM)